Cure My Disease

Don't miss your cure!

 Log in / Sign up

New fibroid Drug's hidden danger? study probes blood clot risk

NCT ID NCT07173127

Recruiting now Knowledge-focused Sponsor: University Hospital, Geneva Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether Ryeqo, a newer hormone treatment for uterine fibroids and endometriosis, increases the risk of dangerous blood clots. Researchers will take blood samples from 30 women before they start Ryeqo and again after 3 months of treatment. The goal is to measure changes in clotting markers to better understand the drug's safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE FIBROID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis leiomyoma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE FIBROID

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpitaux Universitaires de Genève

    RECRUITING

    Geneva, Canton of Geneva, 1205, Switzerland

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••